SEC Form SC 13G/A filed by G1 Therapeutics Inc. (Amendment)
$GTHX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $7.00 → $10.00 | Underweight → Neutral | JP Morgan |
| 1/3/2023 | $32.00 → $31.00 | Buy | Needham |
| 11/4/2021 | $20.00 → $19.00 | Neutral → Underweight | JP Morgan |
| 11/4/2021 | $78.00 → $71.00 | Buy | HC Wainwright & Co. |
| 11/4/2021 | $41.00 → $24.00 | Outperform | Raymond James |
| 10/15/2021 | $51.00 | Buy | BTIG Research |
| 9/30/2021 | $24.00 → $20.00 | Overweight → Neutral | JP Morgan |
| 9/1/2021 | $57.00 → $56.00 | Buy | Roth Capital |
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi
JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously
Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously
JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously